# US 2012/0252815 A1 · Inhibitors of sphingosine kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252815 A1
- Document ID: US20120252815A1
- Status: Published application
- Kind: A1
- Application number: 13/516,370
- Filed: 2010-11-18
- Published: 2012-10-04
- Earliest claimed: 2009-12-17
- Assignees: Merck Patent GmbH
- Inventors: Frank Stieber; Dirk Wienke
- Web page: https://patentgrep.com/patent/US20120252815A1

## CPC

- C07D 249/06: with aryl radicals directly attached to ring atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/10: Anti-acne agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/40: Unsubstituted amino or imino radicals
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, Y1, Y2, V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

## Claims

### Claim 1

Compounds of the formula (I)
in which, in each case independently of one another:
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 denote H, D (deuterium), A, OR18, CN, F, Cl and NR18R18′;
where R1 and R2, R3 and R4, R5 and R6, R10 and R11, R12 and R13, R14 and R15, R16 and R17 together may in each case also form ═O (carbonyl oxygen);
where R9 and R1, R1 and R2, R2 and R3, R3 and R4, R4 and R5, R5 and R6, R6 and R7, R7 and R8, R10 and R11, R11 and R12, R12 and R13, R14 and R15, R15 and R16, R16 and R17 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms or Het having 3, 4, 5, 6 or 7 ring atoms;
where R10 and R19, if Y1═CR19, R11 and R12, R13 and R19, if Y2═CR19, R14 and R19, if Y1═CR19, R15 and R16, R17 and R19, if Y2═CR19, together may in each case also form a C═C double bond with the single bond and the C atoms to which they are attached;
R18, R18′ denote H, D or A;
R19, R19′ denote H, D, A, OR18, NR18R18′, C(O)OR18, C(O)NR F, Cl, Br, CN, Het or A-Het;
M1, M2, M3, denote CR19, N, S or O;
Y1, Y2 denote CR19 or N;
V denotes C(R19)(R19′), NR19 or is absent;
W denotes C(R19)(R19′)]pZ, CO—[C(R19)(R19′)]pZ, [C(R19)(R19′)]pN(R19)—Z, CO—N(R19)—[C(R19)(R19′)]pZ, N(R19)—CO—[C(R19)(R19′)]pZ, CO—O—[C(R19)(R19′)]pZ, C(O)OR19, OR19, H or D;
where V, W and Y2 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may preferably be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′), or Het having 3, 4, 5, 6 or 7 ring atoms, where Het preferably represents a saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ, ═S, ═NH, ═NA, oxy (—O−) and/or ═O (carbonyl oxygen);
Z denotes Het, Ar or A;
A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′);
and/or in which one or two CH2 groups may be replaced by O, S, SO, SO2, CO, COO, NR18, NR18CO, CONR18, cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, CH═CH and/or CH≡CH groups;
or cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′);
Ar denotes phenyl, naphthyl or biphenyl, each of which is mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ,
Het in each case, independently of one another, denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ, ═S, ═NH, ═NA, oxy (—O−) and/or ═O (carbonyl oxygen),
m denotes 1, 2 or 3,
n, o denote 0, 1 or 2,
p denotes 0, 1, 2, 3 or 4
with the proviso that compounds of the formula (I) in which
(a) M1=N, M2=CR19, M3=S, and
(b) Y1═CH and Y2═N, and
(c) n=1 and o=1 are excluded;
and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 2 (depends on 1)

Compounds according to claim 1, in which, in each case independently of one another:
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 denote H, D, F, OR18 or A;
where R1 and R2, R3 and R4, R5 and R6, R10 and R11, R12 and R13, R14 and R15, R16 and R17 together may in each case also form ═O (carbonyl oxygen);
where R9 and R1, R1 and R2, R2 and R3, R3 and R4, R4 and R5, R5 and R6, R6 and R7, R7 and R8; R10 and R11, R11 and R12, R12 and R13, R14 and R15, R15 and R16, R16 and R17 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms or Het having 3, 4, 5, 6 or 7 ring atoms;
R19, R19′ denote H, A, OR18, C(O)OR18, C(O)NR18R18′, A-Het;
M1 denotes N, and M2 denotes CR19 and M3 denotes S; or
M1 denotes N, and M2 denotes S and M3 denotes CR19; or
M1 denotes O, and M2 denotes N and M3 denotes CR19; or
M1 denotes N, and M2 denotes O and M3 denotes CR19; or
M1 denotes S, and M2 denotes N and M3 denotes N; or
M1 denotes S, and M2 denotes N and M3 denotes CR19; or
M1 denotes O, and M2 denotes N and M3 denotes N; or
M1 denotes N, and M2 denotes N and M3 denotes 0; or
M1 denotes N, and M2 denotes N and M3 denotes S; or
M1 denotes CR19, and M2 denotes N and M3 denotes 0; or
M1 denotes CR19, and M2 denotes O and M3 denotes N;
Y1 denotes N, and Y2 denotes CR19; or
Y1 denotes N, and Y2 denotes N; or
Y1 denotes CR19, and Y2 denotes N; or
Y1 denotes CR19, and Y2 denotes CR19;
V denotes C(R19)(R19′), NR19 or is absent;
W denotes [C(R19)(R19′)]pZ, CO—[C(R19)(R19′)]pZ, CO—O—[C(R19)(R19′)]pZ, CO—N(R19)—[C(R19)(R19′)]pZ, [C(R19)(R19′)]pN(R19)—Z, N(R19)—CO—[C(R19)(R19′)]pZ, C(O)OR19, OR19 or H;
where V, W and Y2 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may preferably be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′), or Het having 3, 4, 5, 6 or 7 ring atoms, where Het preferably represents a saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ, ═S, ═NH, ═NA, oxy (—O−) and/or ═O (carbonyl oxygen);
Z denotes Het or A;
m denotes 1 or 2;
p denotes 0, 1, 2 or 3;
and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 3

Compounds selected from the group consisting of:
and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 4 (depends on 1)

Process for the preparation of compounds according to claim 1 and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, characterised in that
(a) a compound of the formula (II)
in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and m have the meanings indicated in claim 1, and L1 has the meaning indicated below,
is reacted with a compound of the formula (III)
in which R10, R11, R12, R13, R14, R15, R16, R17, Y1, Y2, V, n, and o have the meanings indicated in claim 1, L2 has the meaning indicated below, “V-H” is optionally provided with a protecting group (“V-protecting group”), and subsequent steps indicated below are optionally also carried out,
and
(b) the compound of the formula (IV)
in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, Y1, Y2, V, m, n, and o and m [lacuna] the meanings indicated in claim 1,
resulting from step (a) is optionally freed from the protecting group (“V-protecting group”) and reacted with a compound of the formula (V)
L-W (V)
in which W has the meaning indicated in claim 1, and L denotes Cl, Br, I or a free or reactively functionally modified OH group,
or
(c) they are liberated from one of their functional derivatives (for example containing protecting groups) by treatment with an acidic, basic, solvolysing or hydrogenolysing agent,
and/or a base or acid of the formula (I) is converted into one of its salts.

### Claim 5 (depends on 1)

Medicaments comprising one or more compounds according to claim 1 and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 6 (depends on 1)

Medicaments comprising one or more compounds according to claim 1 and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1 by the compounds according to claim 1.

### Claim 7 (depends on 6)

Medicaments according to claim 6, where the diseases to be treated are selected from the group consisting of: “hyperproliferative disease, inflammatory disease, angiogenic disease, fibrotic disease of the lung, kidney, liver and the heart, cancer (tumour disease), atherosclerosis, restenosis, proliferative disease of the mesangial cells, psoriasis, tumour of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx, the lung, the skin, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, transplant rejection, glomerulopathy, inflammatory bowel disease, arthritis, asthma, allergies, inflammatory kidney diseases, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory skin diseases, pardontal diseases, T-cell-promoted immune disease, ulcerative colitis, Crohn's disease, non-specific colitis, allergic encephalomyelitis, allergic neuritis, transplant rejection, graft-versus-host reaction, myocarditis, thyroiditis, nephritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus, rheumatoid arthritis, osteoarthritis, Caplan's syndrome, Felty's syndrome, Sjogren's syndrome, spondylitis ankylosans, Still's disease, chondrocalcinosis, metabolic arthritis, rheumatic fever, Reiter's disease, Wissler's syndrome, glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture's syndrome, Wegener's granulomatosis, renal vasculitis, IgA nephropathy, idiopatic glomerular disease, atopic dermatitis, contact sensitivity, acne, diabetic retinopathy, Kaposi's sarcoma, haemangioma, myocardial angiogenesis, atherosclerotic plaque neovascularisation, angiogenic eye diseases, choroidal neovascularisation, retrolental fibroplasia, macular degeneration, corneal transplant rejection, rubeosis iridis, neuroscular glaucoma, Oster Webber syndrome”.

### Claim 8 (depends on 5)

Medicaments according to claim 5, in which a medicament of this type comprises at least one additional pharmacologically active substance (therapeutic agent, drug, ingredient).

### Claim 9 (depends on 5)

Medicaments according to claim 5, in which the medicament is used before and/or during and/or after treatment with at least one additional pharmacologically active substance.

### Claim 10 (depends on 1)

Pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1.

### Claim 11 (depends on 10)

Pharmaceutical composition according to claim 10 comprising at least one additional compound selected from the group consisting of physiologically acceptable extenders, adjuvants, additives, diluents, excipients and/or additional pharmaceutically active substance.

### Claim 12 (depends on 1)

Kit comprising a therapeutically effective amount of at least one compound according to claim 1 and a therapeutically effective amount of at least one further pharmacologically active substance apart from the compounds according to claim 1.

### Claim 13

Compounds selected from the group consisting of:

### Claim 14 (depends on 6)

Method for the treatment of diseases according to claim 6 comprising the administration of the one or more compounds.
